Jerome B. Zeldis - 05 Apr 2022 Form 4 Insider Report for NexImmune, Inc.

Reporting relationship: Executive VP of Research & Dev
Issuer ticker: N/A
Reported as of: 05 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Apr 2022, 19:12:21 UTC
Prior SEC filing: 28 Mar 2022
Next SEC filing: 21 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Ilse Johnson, Attorney-in-fact

Key filing fact

Jerome B. Zeldis filed Form 4 for NexImmune, Inc. on 07 Apr 2022.

Key facts

This page summarizes Jerome B. Zeldis's Form 4 filing for NexImmune, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Apr 2022, 19:12.

Change

Previous filing in this sequence was filed on 28 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NEXI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +80,100
Change %
Price: $0.000000
Shares after: 80,100
Date: 05 Apr 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,100
Exercise price: $4.22
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of this option shall vest and become exercisable on April 5, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to Mr. Zeldis's continued service to the corporation on each vesting date.